{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:29:31Z","timestamp":1782840571985,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation","doi-asserted-by":"crossref","award":["82160474"],"award-info":[{"award-number":["82160474"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Provincial Chinese Medicine Science and Technology Program","award":["2021B686"],"award-info":[{"award-number":["2021B686"]}]},{"name":"Provincial Health Commission Science and Technology Program Project","award":["202210401"],"award-info":[{"award-number":["202210401"]}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"crossref","award":["20202BAB 206018"],"award-info":[{"award-number":["20202BAB 206018"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05760-9","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:19:29Z","timestamp":1751422769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Piperlongumine enhances the antitumor efficacy of PD-1 inhibitors by inducing immunogenic cell death in prostate cancer cells"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhangjie","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Maggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"5760_CR1","doi-asserted-by":"crossref","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70(2):86\u2013104. 10.3322\/caac.21596 Epub 2020 Jan 16. PMID: 31944278","DOI":"10.3322\/caac.21596"},{"issue":"19","key":"5760_CR2","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","volume":"25","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL (2019) The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res 25(19):5743\u20135751. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2641Epub 2019 Apr 30. PMID: 31040150","journal-title":"Clin Cancer Res"},{"issue":"23","key":"5760_CR3","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1158\/1078-0432.CCR-21-2372","volume":"28","author":"C Yao","year":"2022","unstructured":"Yao C, Zhang T, Wu T, Brugarolas J (2022) Facts and hopes for immunotherapy in renal cell carcinoma. Clin Cancer Res 28(23):5013\u20135020. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2372PMID: 35819272; PMCID: PMC9835201","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5760_CR4","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A (2023) Ipilimumab with or without nivolumab in PD-1 or PD-L1 Blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278\u20132285. https:\/\/doi.org\/10.1038\/s41591-023-02498-yEpub 2023 Aug 17. PMID: 37592104; PMCID: PMC10708907","journal-title":"Nat Med"},{"issue":"12","key":"5760_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","volume":"35","author":"S van Wilpe","year":"2024","unstructured":"van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, Coskunturk M, Osinga T, Bloemendal H, Adema G, Smeenk RJ, Nagarajah J, van Ipenburg J, Kroeze LI, Ligtenberg MJL, Schalken J, Gerritsen WR, Mehra N (2024) Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Ann Oncol 35(12):1126\u20131137 Epub 2024 Sep 16. PMID: 39293514","journal-title":"Ann Oncol"},{"issue":"1","key":"5760_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ymthe.2022.09.001","volume":"31","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yue X, Liu H, Zhu Y, Ke H, Yang X, Yin S, Li Z, Zhang Y, Hu T, Lan P, Wu X (2023) MAP7D2 reduces CD8\u2009+\u2009cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. Mol Ther 31(1):90\u2013104 Epub 2022 Sep 8. PMID: 36081350; PMCID: PMC9840115","journal-title":"Mol Ther"},{"issue":"2","key":"5760_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.21037\/tcr-20-2738","volume":"10","author":"B Wang","year":"2021","unstructured":"Wang B, Xu Z, Sunthamala N, Yaguchi T, Huang J, Kawakami Y, Gong Y, Tang H, Li S, Guo Y, Guo Y, Jinushi M (2021) Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells. Transl Cancer Res 10(2):899\u2013913. https:\/\/doi.org\/10.21037\/tcr-20-2738PMID: 35116419; PMCID: PMC8798308","journal-title":"Transl Cancer Res"},{"issue":"1","key":"5760_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S (2018) High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6(1):157","journal-title":"J Immunother Cancer"},{"issue":"22","key":"5760_CR9","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","volume":"23","author":"M Bilusic","year":"2017","unstructured":"Bilusic M, Madan RA, Gulley JL (2017) Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res 23(22):6764\u20136770","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5760_CR10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","volume":"67","author":"R Ben-Avi","year":"2018","unstructured":"Ben-Avi R, Farhi R, Ben-Nun A et al (2018) Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 67(8):1221\u20131230","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"5760_CR11","doi-asserted-by":"publisher","first-page":"2219591","DOI":"10.1080\/2162402X.2023.2219591","volume":"12","author":"J Sprooten","year":"2023","unstructured":"Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, Naulaerts S, Borras DM, Kinget L, Fuc\u00edkov\u00e1 J, \u0160p\u00ed\u0161ek R, Jel\u00ednkov\u00e1 LP, Kepp O, Kroemer G, Krysko DV, Coosemans A, Vaes RDW, De Ruysscher D, De Vleeschouwer S, Wauters E, Smits E, Tejpar S, Beuselinck B, Hatse S, Wildiers H, Clement PM, Vandenabeele P, Zitvogel L, Garg AD (2023) Trial watch: chemotherapy-induced Immunogenic cell death in oncology. Oncoimmunology 12(1):2219591 PMID: 37284695; PMCID: PMC10240992","journal-title":"Oncoimmunology"},{"issue":"5","key":"5760_CR12","doi-asserted-by":"publisher","first-page":"188946","DOI":"10.1016\/j.bbcan.2023.188946","volume":"1878","author":"S Yu","year":"2023","unstructured":"Yu S, Xiao H, Ma L, Zhang J, Zhang J (2023) Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochim Biophys Acta Rev Cancer 1878(5):188946. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188946Epub 2023 Jun 27. PMID: 37385565","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5760_CR13","doi-asserted-by":"publisher","unstructured":"(2022) Immune checkpoint blockade enhances efficacy of neoantigen vaccine. Cancer Discov 12(6):1408. https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2022-065PMID: 35426915","DOI":"10.1158\/2159-8290.CD-RW2022-065"},{"issue":"7","key":"5760_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND, Liu G, Matheson D, Murphy L, Oldroyd RE, Parmar MKB, Rogozinska E, Sfumato P, Sweeney CJ, Sydes MR, Tombal B, White IR, Tierney JF, STOPCAP Collaboration (2023) Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol 24(7):783\u2013797 PMID: 37414011; PMCID: PMC7616350","journal-title":"Lancet Oncol"},{"issue":"9","key":"5760_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1021\/acschembio.5b00268","volume":"10","author":"SR Jean","year":"2015","unstructured":"Jean SR, Tulumello DV, Riganti C et al (2015) Mitochondrial targeting of doxorubicin eliminates nuclear effects associated with cardiotoxicity. ACS Chem Biol 10(9):2007\u20132015","journal-title":"ACS Chem Biol"},{"issue":"1","key":"5760_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","volume":"8","author":"B Seruga","year":"2011","unstructured":"Seruga B, Ocana A, Tannock IF (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8(1):12\u201323","journal-title":"Nat Rev Clin Oncol"},{"key":"5760_CR17","doi-asserted-by":"publisher","first-page":"114554","DOI":"10.1016\/j.biopha.2023.114554","volume":"161","author":"C Shi","year":"2023","unstructured":"Shi C, Huang K, Soto J, Sankaran R, Kalia V, Onwumere O, Young M, Einbond L, Redenti S (2023) Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles. Biomed Pharmacother 161:114554. https:\/\/doi.org\/10.1016\/j.biopha.2023.114554Epub 2023 Mar 20. PMID: 36940616; PMCID: PMC10157982","journal-title":"Biomed Pharmacother"},{"key":"5760_CR18","doi-asserted-by":"publisher","first-page":"104772","DOI":"10.1016\/j.phrs.2020.104772","volume":"156","author":"SK Tripathi","year":"2020","unstructured":"Tripathi SK, Biswal BK (2020) Piperlongumine, a potent anticancer phytotherapeutic: perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacol Res 156:104772. https:\/\/doi.org\/10.1016\/j.phrs.2020.104772Epub 2020 Apr 10. PMID: 32283222","journal-title":"Pharmacol Res"},{"issue":"9","key":"5760_CR19","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.3390\/ijms24098048","volume":"24","author":"TH Lin","year":"2023","unstructured":"Lin TH, Kuo CH, Zhang YS, Chen PT, Chen SH, Li YZ, Lee YR (2023) Piperlongumine induces cellular apoptosis and autophagy via the ros\/akt signaling pathway in human follicular thyroid Cancer cells. Int J Mol Sci 24(9):8048. https:\/\/doi.org\/10.3390\/ijms24098048PMID: 37175755; PMCID: PMC10179299","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5760_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A et al (2021) Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther 20(3):577\u2013588","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"5760_CR21","first-page":"1266","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Hu P, Ding SY et al (2019) Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug Disulfiram. Am J Cancer Res 9(6):1266\u20131281","journal-title":"Am J Cancer Res"},{"key":"5760_CR22","doi-asserted-by":"publisher","unstructured":"Liu W, Zhu Y, Ye L, Zhu Y, Wang Y (2022) Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate. BMC Cancer 22(1):173. https:\/\/doi.org\/10.1186\/s12885-022-09266-0. Erratum in: BMC Cancer. 2022 Feb 22;22(1):200. doi: 10.1186\/s12885-022-09310-z PMID: 35168543; PMCID: PMC8848828","DOI":"10.1186\/s12885-022-09266-0"},{"issue":"3","key":"5760_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/or.2021.7933","volume":"45","author":"X Fu","year":"2021","unstructured":"Fu X, Cui J, Meng X, Jiang P, Zheng Q, Zhao W, Chen X (2021) Endoplasmic reticulum stress, cell death and tumor: association between endoplasmic reticulum stress and the apoptosis pathway in tumors (Review). Oncol Rep 45(3):801\u2013808. https:\/\/doi.org\/10.3892\/or.2021.7933Epub 2021 Jan 12. PMID: 33469681; PMCID: PMC7859917","journal-title":"Oncol Rep"},{"issue":"5","key":"5760_CR24","doi-asserted-by":"publisher","first-page":"e16246","DOI":"10.1016\/j.heliyon.2023.e16246","volume":"9","author":"M Fan","year":"2023","unstructured":"Fan M, Zhang J, Zeng L, Wang D, Chen J, Xi X, Long J, Huang J, Li X (2023) Non-coding RNA mediates endoplasmic reticulum stress-induced apoptosis in heart disease. Heliyon 9(5):e16246. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16246PMID: 37251826; PMCID: PMC10209419","journal-title":"Heliyon"},{"issue":"6","key":"5760_CR25","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1021\/jacs.3c08622","volume":"146","author":"Y Liu","year":"2024","unstructured":"Liu Y, Niu R, Zhao H, Wang Y, Song S, Zhang H, Zhao Y (2024) Single-Site nanozymes with a highly conjugated coordination structure for antitumor immunotherapy via cuproptosis and cascade-enhanced T lymphocyte activity. J Am Chem Soc 146(6):3675\u20133688. https:\/\/doi.org\/10.1021\/jacs.3c08622Epub 2024 Feb 2. PMID: 38305736","journal-title":"J Am Chem Soc"},{"key":"5760_CR26","doi-asserted-by":"publisher","first-page":"216676","DOI":"10.1016\/j.canlet.2024.216676","volume":"586","author":"X Hu","year":"2024","unstructured":"Hu X, Zhao M, Bai M, Xue Z, Wang F, Zhu Z, Yu J, Yue J (2024) PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation. Cancer Lett 586:216676 Epub 2024 Jan 24. PMID: 38278469","journal-title":"Cancer Lett"},{"key":"5760_CR27","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.2147\/IJN.S454004","volume":"19","author":"MR Zhang","year":"2024","unstructured":"Zhang MR, Fang LL, Guo Y, Wang Q, Li YJ, Sun HF, Xie SY, Liang Y (2024) Advancements in stimulus-responsive co-delivery nanocarriers for enhanced cancer immunotherapy. Int J Nanomed 19:3387\u20133404 PMID: 38617801; PMCID: PMC11012697","journal-title":"Int J Nanomed"},{"issue":"4","key":"5760_CR28","doi-asserted-by":"publisher","first-page":"102357","DOI":"10.1016\/j.omtn.2024.102357","volume":"35","author":"C Zhang","year":"2024","unstructured":"Zhang C, Huang R, Ren L, Martincuks A, Song J, Kortylewski M, Swiderski P, Forman SJ, Yu H (2024) Local CpG-Stat3 SiRNA treatment improves antitumor effects of immune checkpoint inhibitors. Mol Ther Nucleic Acids 35(4):102357. https:\/\/doi.org\/10.1016\/j.omtn.2024.102357PMID: 39618825; PMCID: PMC11605413","journal-title":"Mol Ther Nucleic Acids"},{"key":"5760_CR29","doi-asserted-by":"publisher","first-page":"114392","DOI":"10.1016\/j.biopha.2023.114392","volume":"160","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A (2023) Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother 160:114392. https:\/\/doi.org\/10.1016\/j.biopha.2023.114392Epub 2023 Feb 15. PMID: 36804123","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5760_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s11010-020-04044-7","volume":"476","author":"S Kumar","year":"2021","unstructured":"Kumar S, Agnihotri N (2021) Piperlongumine targets NF-\u03baB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer. Mol Cell Biochem 476(4):1765\u20131781. https:\/\/doi.org\/10.1007\/s11010-020-04044-7Epub 2021 Jan 12. PMID: 33433833","journal-title":"Mol Cell Biochem"},{"key":"5760_CR31","doi-asserted-by":"publisher","unstructured":"Qiu J, Guo F, Shi J, Guo T, Piao H (2024) Piperlongumine inhibits glioblastoma proliferation by inducing ferroptosis. J Pharm Pharmacol:rgae148. https:\/\/doi.org\/10.1093\/jpp\/rgae148 Epub ahead of print. PMID: 39692457","DOI":"10.1093\/jpp\/rgae148"},{"issue":"1","key":"5760_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/pros.22535","volume":"73","author":"KV Golovine","year":"2013","unstructured":"Golovine KV, Makhov PB, Teper E et al (2013) Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 73(1):23\u201330","journal-title":"Prostate"},{"issue":"1","key":"5760_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12906-021-03369-0","volume":"21","author":"DF Zhang","year":"2021","unstructured":"Zhang DF, Yang ZC, Chen JQ, Jin XX, Qiu YD, Chen XJ, Shi HY, Liu ZG, Wang MS, Liang G, Zheng XH (2021) Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage. BMC Complement Med Ther 21(1):195. https:\/\/doi.org\/10.1186\/s12906-021-03369-0PMID: 34229670; PMCID: PMC8261967","journal-title":"BMC Complement Med Ther"},{"issue":"14","key":"5760_CR34","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1016\/j.bmcl.2018.05.025","volume":"28","author":"YH Kim","year":"2018","unstructured":"Kim YH, Yoon YJ, Lee YJ et al (2018) Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells. Bioorg Med Chem Lett 28(14):2566\u20132572","journal-title":"Bioorg Med Chem Lett"},{"key":"5760_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.redox.2018.10.006","volume":"20","author":"MS Oliveira","year":"2019","unstructured":"Oliveira MS, Barbosa MIF, de Souza TB, Moreira DRM, Martins FT, Villarreal W, Machado RP, Doriguetto AC, Soares MBP, Bezerra DP (2019) A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK\/p38 pathway in human acute promyelocytic leukemia HL-60 cells. Redox Biol 20:182\u2013194 Epub 2018 Oct 12. PMID: 30359932; PMCID: PMC6198128","journal-title":"Redox Biol"},{"key":"5760_CR36","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3389\/fphar.2019.01178","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, He LJ, Zhu YB et al (2019) Piperlongumine inhibits Akt phosphorylation to reverse resistance to cisplatin in human non-small cell lung cancer cells via ROS regulation. Front Pharmacol 10:1178","journal-title":"Front Pharmacol"},{"issue":"1","key":"5760_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2022.01.01","volume":"34","author":"D Ti","year":"2022","unstructured":"Ti D, Yan X, Wei J, Wu Z, Wang Y, Han W (2022) Inducing Immunogenic cell death in immuno-oncological therapies. Chin J Cancer Res 34(1):1\u201310. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2022.01.01PMID: 35355932; PMCID: PMC8913252","journal-title":"Chin J Cancer Res"},{"key":"5760_CR38","doi-asserted-by":"publisher","first-page":"114503","DOI":"10.1016\/j.biopha.2023.114503","volume":"161","author":"H Aria","year":"2023","unstructured":"Aria H, Rezaei M (2023) Immunogenic cell death inducer peptides: a new approach for cancer therapy, current status and future perspectives. Biomed Pharmacother 161:114503. https:\/\/doi.org\/10.1016\/j.biopha.2023.114503Epub 2023 Mar 13. PMID: 36921539","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5760_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","volume":"21","author":"I Martins","year":"2014","unstructured":"Martins I, Wang Y, Michaud M et al (2014) Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21(1):79\u201391","journal-title":"Cell Death Differ"},{"key":"5760_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2020.00229","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Deng M, Loughran PA, Yang M, Lin M, Yang C, Gao W, Jin S, Li S, Cai J, Lu B, Billiar TR, Scott MJ (2020) LPS induces active HMGB1 release from hepatocytes into exosomes through the coordinated activities of TLR4 and Caspase-11\/GSDMD signaling. Front Immunol 11:229. https:\/\/doi.org\/10.3389\/fimmu.2020.00229PMID: 32328059; PMCID: PMC7160675","journal-title":"Front Immunol"},{"key":"5760_CR41","doi-asserted-by":"publisher","first-page":"112986","DOI":"10.1016\/j.fct.2022.112986","volume":"163","author":"T He","year":"2022","unstructured":"He T, Wang Q, Ao J, Chen K, Li X, Zhang J, Duan C (2022) Endoplasmic reticulum stress contributes to autophagy and apoptosis in cantharidin-induced nephrotoxicity. Food Chem Toxicol 163:112986. https:\/\/doi.org\/10.1016\/j.fct.2022.112986Epub 2022 Apr 6. PMID: 35398186","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"5760_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.5757","volume":"255","author":"LB Andersen","year":"2021","unstructured":"Andersen LB, N\u00f8rgaard M, Rasmussen M, Freds\u00f8e J, Borre M, Ulh\u00f8i BP, S\u00f8rensen KD (2021) Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol 255(2):155\u2013165 Epub 2021 Aug 10. PMID: 34255349","journal-title":"J Pathol"},{"key":"5760_CR43","doi-asserted-by":"publisher","first-page":"e15013","DOI":"10.7717\/peerj.15013","volume":"11","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhang P, Zhao Z, Wang J, Zhang H (2023) Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer. PeerJ 11:e15013. https:\/\/doi.org\/10.7717\/peerj.15013PMID: 37070095; PMCID: PMC10105558","journal-title":"PeerJ"},{"issue":"17","key":"5760_CR44","doi-asserted-by":"publisher","first-page":"e2206889","DOI":"10.1002\/advs.202206889","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang D, Cheng C, Chen X, Wang J, Liu K, Jing N, Xu P, Xi X, Sun Y, Ji Z, Zhao H, He Y, Zhang K, Du X, Dong B, Fang Y, Zhang P, Qian X, Xue W, Gao WQ, Zhu HH (2023) IL-1\u03b2 is an Androgen-Responsive target in macrophages for immunotherapy of prostate Cancer. Adv Sci (Weinh) 10(17):e2206889. https:\/\/doi.org\/10.1002\/advs.202206889Epub 2023 Apr 24. PMID: 37092583; PMCID: PMC10265092","journal-title":"Adv Sci (Weinh)"},{"key":"5760_CR45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.actbio.2023.07.018","volume":"168","author":"Y Wang","year":"2023","unstructured":"Wang Y, Lei H, Yan B, Zhang S, Xu B, Lin M, Shuai X, Huang J, Pang J (2023) Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer. Acta Biomater 168:593\u2013605 Epub 2023 Jul 18. PMID: 37474083","journal-title":"Acta Biomater"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05760-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:04:15Z","timestamp":1767996255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05760-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5760"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05760-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"406"}}